Autistic disorder
Drug research and approvals for autistic disorder: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 356 studies of autistic disorder are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 356
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Evaluation of the TAP-Preschool (TAP-P) for Tele-assessment of Autism in Preschool-aged ChildrenNCT07932665 · Not applicable · Vanderbilt University Medical Center · starts Oct 4, 2026
- Effects of Transcranial Direct Current Stimulation for Enhancing Cognitive Function in Individuals With Autism Spectrum…NCT07931781 · Not applicable · The Hong Kong Polytechnic University · starts Nov 16, 2026
- SIT and Deep Pressure Therapy Effects on Motor Coordination in Children With ASDNCT07911904 · Not applicable · Riphah International University · starts Jul 1, 2026
- Effectiveness of Clown Therapy in Facilitating Dental Visits for Children With Autism Spectrum DisorderNCT07906288 · Not applicable · University of Milan · starts Nov 10, 2026
- Effectiveness of the Autism Pupil Screen (APS) Detect Pupillometer for Identifying Autism Spectrum Disorder (ASD) in…NCT07903675 · Not reported · Schweitzer Engineering Laboratories · starts Oct 23, 2026
- TRIal of PPF3 vs. PlaCEbo in the TReatment of Children and AdolescenTs With NeurOdeveloPmental DisorderSNCT07893964 · Phase 2 · Holland Bloorview Kids Rehabilitation Hospital · starts Nov 1, 2026
- Multi-Omics Genetic Investigation Strategies to Enhance the Diagnostic Workflow for Rare DiseasesNCT07884227 · Not reported · Istituto Giannina Gaslini · starts Sep 4, 2023
- French Minds Cohort: a French Longitudinal and Multimodal Cohort of Patients With Major Mood Disorders, Psychotic…NCT07881016 · Not applicable · Fondation FondaMental · starts Jun 11, 2026
- Interactive Massage Intervention in Toddlers With Autism Spectrum DisorderNCT07876245 · Not applicable · Children's Hospital of Fudan University · starts Sep 1, 2025
Approved 3
- AripiprazoleDopamine D2 receptor partial agonist
- RisperidoneSerotonin 2a (5-HT2a) receptor antagonist
- MelatoninMelatonin receptor agonist
Phase 3 12 of 16
- FluoxetineSerotonin transporter inhibitor
- ChymotrypsinPolypeptides proteolytic enzyme
- Valproic acidSuccinate semialdehyde dehydrogenase inhibitor
- CycloserineD-alanylalanine synthetase inhibitor
- Sulforaphane
- BumetanideSodium-(potassium)-chloride cotransporter 2 inhibitor
- Secretin synthetic humanSecretin receptor agonist
- MemantineGlutamate [NMDA] receptor negative allosteric modulator
- FluvoxamineSerotonin transporter inhibitor
- LurasidoneSerotonin 2a (5-HT2a) receptor antagonist
- SertralineSerotonin transporter inhibitor
- AtomoxetineNorepinephrine transporter inhibitor
Phase 2 12 of 28
- OxytocinOxytocin receptor agonist
- AcetylcysteineGlutathione precursor
- OlanzapineSerotonin 2a (5-HT2a) receptor antagonist
- BuspironeSerotonin 1a (5-HT1a) receptor partial agonist
- CholecalciferolVitamin D receptor agonist
- EsomeprazolePotassium-transporting ATPase inhibitor
- SuccimerLead chelating agent
- Cannabinol
- Racemetyrosine
- CitalopramSerotonin transporter inhibitor
- LenalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- QuinidineSodium channel alpha subunit blocker
Phase 1 or earlier 12
- BaclofenGABA-B receptor agonist
- AcamprosateGlutamate [NMDA] receptor antagonist
- MecamylamineNeuronal acetylcholine receptor; alpha3/beta4 negative allosteric modulator
- MinocyclineBacterial 70S ribosome inhibitor
- Ascorbic acidSupplement
- GTS-21Neuronal acetylcholine receptor protein alpha-7 subunit agonist
- OxygenEssential for cellular homeostasis
- Maltodextrin
- Cholesterol
- Zinc ion
- RO-5028442
- TretinoinRetinoic acid receptor agonist
How its trials ended
1,275 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 191 whose ending is known, 47% met their primary endpoint, 10% missed it and 43% stopped early.
- Completed, result not reported57145%
- Ongoing36028%
- Status unknown15312%
- Met its primary endpoint897%
- Stopped: other or unclear574%
- Missed its primary endpoint191%
- Stopped: lack of efficacy101%
- Stopped: enrollment or feasibility81%
- Stopped: sponsor or business decision4<1%
- Stopped: funding4<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA